Çocukluk Çağı Nörolojik Hastalıklarda Gen Tedavisi
Özet
Gen tedavisi, eksik veya hatalı genlerin düzeltilmesi amacıyla DNA veya RNA moleküllerinin hücrelere aktarılması esasına dayanır ve çocukluk çağı nörolojik hastalıklarının tedavisinde yeni bir çığır açmaktadır. Spesifik viral vektörler veya gen düzenleme yöntemleri (CRISPR/Cas9 gibi) kullanılarak Spinal Müsküler Atrofi (SMA) ve Duchenne Müsküler Distrofi (DMD) gibi genetik kökenli hastalıkların altta yatan nedenlerine yönelik müdahaleler gerçekleştirilmektedir. Ancak, merkezi sinir sisteminin karmaşık yapısı ve tedavi süreçlerindeki güvenlik kaygıları, uygulamaların etkinliğini artırmak için çözüm bekleyen teknik zorluklar oluşturmaktadır. Güncel araştırmalar, bu yöntemlerin rutin klinik kullanıma daha güvenli ve etkili bir şekilde entegre edilmesi üzerine yoğunlaşmaktadır.
Gene therapy, based on the transfer of DNA or RNA molecules into cells to correct missing or faulty genes, is opening new horizons in the treatment of pediatric neurological diseases. By utilizing specific viral vectors or gene editing techniques like CRISPR/Cas9, interventions are being developed to address the root causes of genetic disorders such as Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD). However, the complex structure of the central nervous system and safety concerns during treatment pose technical challenges that need resolution to improve efficacy. Current research focuses on integrating these methods more safely and effectively into routine clinical practice.
Referanslar
Alnasser SM. Review on mechanistic strategy of gene therapy in the treatment of disease Gene. 2021Feb15;769:145246.
Privolizzi R, Chu WS, Tijani M, Ng J. Viral gene therapy for paediatric neurological diseases: progress to clinical reality. Dev Med Child Neurol. 2021 Apr 9. doi: 10.1111/dmcn.14885.
High KA, Roncarolo MG. Gene Therapy. N Engl J Med. 2019;381:455.
Flomenberg P, Daniel R. Overview of gene therapy, gene editing, and gene silencing. Uptodate. 2021.
Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 2000;60(2):249-71.
Piguet F, Alves S, Cartier N. Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future. Hum Gene Ther. 2017;28(11):988-1003.
Penaa SA, Iyengara R_, Rebecca S, et al. Gene therapy for neurological disorders: challenges and recent advancements. J. Drug Targeting. 2020:28:111–128.
Alnasser SM. Review on mechanistic strategy of gene therapy in the treatment of disease. Gene. 2021:15;769:145246.
Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 2000 Aug;60(2):249-71.
Ojala DS, Amara DP, Schaffer DV. Adeno-associated virus vectors and neurological gene therapy. Neuroscientist. 2015Feb;21(1):84-98.
Weinberg MS, Samulski RJ, McCown TJ. Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology. 2013;69:82-8.
Padhy SK, Takkar B, Narayanan R, Venkatesh P, Jalali S. Voretigene Neparvovec and Gene Therapy for Leber's Congenital Amaurosis: Review of Evidence to Date. Appl Clin Genet. 2020Nov 25;13:179-208.
Cehajic Kapetanovic J, McClements ME, Martinez-Fernandez de la Camara C, MacLaren RE. Molecular Strategies for RPGR Gene Therapy. Genes (Basel). 2019:4;10(9):674.
Lidonnici MR, Ferrari G. Gene therapy and gene editing strategies for hemoglobinopathies. Blood Cells Mol Dis. 2018May;70:87-101.
Makita S, Imaizumi K, Kurosawa S, Tobinai K. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Drugs Context. 2019Feb 13;8:212567.
Karimian A, Azizian K, Parsian H, et al. CRISPR/Cas9 technology as a potent molecular tool for gene therapy. J Cell Physiol. 2019Aug;234(8):12267-12277.
Perez Rojo F, Nyman RKM, Johnson AAT, et al. CRISPR-Cas systems: ushering in the new genome editing era. Bioengineered. 2018;9(1):214-221. 18-Bi H, Yang B. Gene Editing With TALEN and CRISPR/Cas in Rice. Prog Mol Biol Transl Sci. 2017;149:81-98.
Morris KV. Long antisense non-coding RNAs function to direct epigenetic complexes that regulate transcription in human cells. Epigenetics. 2009: 1;4(5):296-301.
Weinberg MS, Morris KV. Long non-coding RNA targeting and transcriptional de-repression. Nucleic Acid Ther. 2013Feb;23(1):9-14.
Lee BH, Collins E, Lewis L,et al. Combination therapy with nusinersen and AVXS-101 in SMA type1. Neurology. 2019; 93:640.
Chen TH. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype toPhenotype to Treatment and Where Do We Stand? Int J Mol Sci. 2020; 21.
Matesanz SE, Curry C, Gross B, et al. Clinical Course in a Patient With Spinal Muscular AtrophyType 0 Treated With Nusinersen and Onasemnogene Abeparvovec. J Child Neurol. 2020; 35:717.
Bodamer OA, Spinal muscular atrophy. Uptodate. 2021.
Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377:1723.
Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy. .Ann Pharmacother. 2020Oct;54(10):1001-1009.
Dhillon S. Risdiplam: First Approval. Drugs. 2020;80(17):1853-1858.
Heslop E, Turner C, Irvin A, et al. Gene therapy in Duchenne muscular dystrophy: Identifying and preparing for the challenges ahead. Neuromuscul Disord. 2021Jan;31(1):69-78.
Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat. Rev Neurol. 2019;15:373–386.
Salmaninejad A, Valilou S.F, Bayat H, et al. Duchenne muscular dystrophy: An updated review of common available therapies. Int. J Neurosci. 2018;128:854–864.
Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchennemuscular dystrophy. Ann Neurol. 2013;74:637.
Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen inpatients with Duchenne muscular dystrophy. Neurology. 2020; 94:e2270.
Dhillon S. Viltolarsen: First Approval. Drugs. 2020;80:1027.
Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutationdystrophinopathy. Muscle Nerve. 2014;50:477.
McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutationDuchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind,placebo-controlled, phase 3 trial. Lancet. 2017;390:1489.
McNally EM. Powerful genes--myostatin regulation of human muscle mass. N Engl J Med. 2004; 350:2642.
Buyse GM, Voit T, Schara U, et al. Efficacy of idebenone on respiratory function in patientswith Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blindrandomised placebo-controlled phase 3 trial. Lancet. 2015;385:1748.
Holley RJ, Wood SR, Bigger BW. Delivering Hematopoietic Stem Cell Gene Therapy Treatmentsfor Neurological Lysosomal Diseases. ACS Chem Neurosci. 2019;10:18.
Sawamoto K, Chen HH, Alméciga-Díaz CJ, Robert W, Mason RW, Tomatsu S. Gene therapy for Mucopolysaccharidoses. Mol Genet Metab. 2018;123:59.
Eichler F, Duncan C, Musolino PL, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2017;377:1630.
Gong Y, Mu D, Prabhakar S, et al. Adenoassociated virus serotype 9-mediated genetherapy for x-linked adrenoleukodystrophy. Mol Ther. 2015;23:824.
